Syros Pharmaceuticals (NASDAQ: SYRS) Receives Notice of Listing Non-ComplianceOn January 6, 2025, Syros Pharmaceuticals, Inc. received deficiency letters from the Nasdaq Stock Market, LLC, highlighting certain non-compliance issues with Nasdaq listin
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Syros Pharmaceuticals’s 8K filing here. About Syros Pharmaceuticals (Get Free Report) Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are […]
12 Jan 09:14 · The Markets Daily